Innovent Biologics, Inc. reported revenue results for the fourth quarter of 2023. In the fourth quarter of 2023, the Company achieved a total product revenue exceeding RMB1.6 billion, representing a robust year-over-year growth of over 65%, along with continuous efforts in enhancing productivity and efficiency under a healthy and sustainable operation model. During the quarter, TYVYT ® (sintilimab injection) continued its strong sales performance and solid market-leading position propelled by its broad indications and National Reimbursement Drug List ("NRDL") coverage.

Besides, the Company's other products also continued rapid ramp-up growth.